Metraipolis › archive › dc_d73b8d0d3702
Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy — Europe PMC PMID:41907622
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41907622
- DOI
- 10.3389/fonc.2026.1763278
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-04T20:35:50.184Z
- SHA-256 of the archived text
fa339f50320793cbe3e1e92a7c9b311e79460d97127d34e4bfe7051a14e4d0c6- Stable URL of this page
https://metraipolis.com/documento/dc_d73b8d0d3702
How to cite
Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy — Europe PMC PMID:41907622 — Europe PMC (en), https://europepmc.org/article/MED/41907622 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d73b8d0d3702 (Metraipolis archive dc_d73b8d0d3702, sha256 fa339f50320793cbe3e1e92a7c9b311e79460d97127d34e4bfe7051a14e4d0c6)
BibTeX
@misc{dcd73b8d0d3702,
title = {Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy — Europe PMC PMID:41907622},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41907622},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d73b8d0d3702; sha256 fa339f50320793cbe3e1e92a7c9b311e79460d97127d34e4bfe7051a14e4d0c6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41907622. Agents can read the archived copy with the MCP tool read_document.